论文部分内容阅读
目的:对比观察替吉奥胶囊与5-氟尿嘧啶(5-FU)治疗晚期直肠癌的疗效及安全性。方法:将2012年2月—2014年2月的晚期直肠癌患者89例随机分为两组,替吉奥组45例,5-FU组44例,两组患者均给予奥沙利铂静脉滴注,替吉奥组在此基础上给予替吉奥胶囊口服治疗,5-FU组在此基础上给予5-FU静脉滴注,两组均接受2个周期以上的全身静脉化疗,在3~6个化疗周期后评价两组临床疗效,统计记录两组化疗期间不良反应情况。结果:两组均完成5个化疗周期,两组总有效率65.17%(58/89),其中替吉奥组总有效为68.89%,5-FU组为61.36%,疾病控制率分别为91.11%、86.36%,两组疗效差异无统计学意义(P>0.05)。5-FU组不良反应较替吉奥组重,其在恶性、呕吐、静脉炎以及口腔黏膜炎方面的不良反应发生率高于替吉奥组,两组比较差异有统计学意义(P<0.05)。结论:替吉奥胶囊联和5-FU用于晚期直肠癌疗效均可靠,但替吉奥胶囊不良反应较轻,更为安全。
Objective: To compare and evaluate the efficacy and safety of tigeo capsule and 5-fluorouracil (5-FU) in the treatment of advanced rectal cancer. Methods: Eighty-nine patients with advanced rectal cancer from February 2012 to February 2014 were randomly divided into two groups. Forty-five patients were in the treatment group and 44 in the 5-FU group. Both groups were given intravenous oxaliplatin Note, on behalf of the group on this basis for the treatment of gioa capsules oral treatment, 5-FU group on this basis given 5-FU intravenous infusion, both groups received more than 2 cycles of systemic intravenous chemotherapy in the 3 ~ After 6 cycles of chemotherapy, the clinical efficacy of the two groups was evaluated, and the adverse reactions of the two groups were recorded statistically. Results: The two chemotherapy regimens were completed in 5 cycles. The total effective rate was 65.17% (58/89) in both groups. The total effective rate in the two groups was 68.89%, that in the 5-FU group was 61.36%, and the disease control rates were 91.11% , 86.36%, there was no significant difference between the two groups (P> 0.05). Adverse reactions were more severe in the 5-FU group than in the substitute group, and the incidence of adverse reactions in malignant, vomiting, phlebitis and oral mucositis was higher in the 5-FU group than in the substitute group (P <0.05 ). CONCLUSION: TEGO capsules combined with 5-FU for the treatment of advanced rectal cancer are reliable, but TIGO capsules have less adverse reactions and are more safe.